Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Current Assets (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Current Assets for 16 consecutive years, with $43.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets fell 6.38% to $43.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $43.8 million, a 6.38% decrease, with the full-year FY2024 number at $45.1 million, down 8.0% from a year prior.
  • Current Assets was $43.8 million for Q3 2025 at Harvard Bioscience, down from $45.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $61.6 million in Q4 2021 to a low of $43.8 million in Q3 2025.
  • A 5-year average of $50.7 million and a median of $50.5 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: increased 27.95% in 2021, then decreased 16.98% in 2022.
  • Harvard Bioscience's Current Assets stood at $61.6 million in 2021, then fell by 16.98% to $51.1 million in 2022, then dropped by 4.08% to $49.0 million in 2023, then fell by 8.0% to $45.1 million in 2024, then fell by 2.91% to $43.8 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Current Assets are $43.8 million (Q3 2025), $45.0 million (Q2 2025), and $44.9 million (Q1 2025).